Automate Your Wheel Strategy on OSCR
With Tiblio's Option Bot, you can configure your own wheel strategy including OSCR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol OSCR
- Rev/Share 40.1223
- Book/Share 5.3173
- PB 2.6088
- Debt/Equity 0.2249
- CurrentRatio 0.0
- ROIC -0.0597
- MktCap 3520433246.0
- FreeCF/Share 4.7413
- PFCF 2.9549
- PE 28.1972
- Debt/Assets 0.0513
- DivYield 0
- ROE 0.1061
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 2
- DCF Score 1
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | OSCR | Robert W. Baird | Outperform | Neutral | -- | $14 | July 25, 2025 |
| Downgrade | OSCR | UBS | Neutral | Sell | -- | $11 | July 15, 2025 |
| Downgrade | OSCR | Piper Sandler | Overweight | Neutral | -- | $14 | July 14, 2025 |
| Downgrade | OSCR | Wells Fargo | Equal Weight | Underweight | -- | $10 | July 11, 2025 |
| Initiation | OSCR | Barclays | -- | Underweight | -- | $17 | July 2, 2025 |
| Downgrade | OSCR | Raymond James | Outperform | Market Perform | -- | -- | June 24, 2025 |
| Downgrade | OSCR | Wells Fargo | Overweight | Equal Weight | $20 | $16 | March 13, 2025 |
| Initiation | OSCR | Jefferies | -- | Underperform | -- | $12 | Dec. 10, 2024 |
| Initiation | OSCR | UBS | -- | Neutral | -- | $23 | Oct. 7, 2024 |
News
Oscar Health: Barclays, UBS, And Wells Fargo Downgraded, But The Real Story Says Buy
Published: July 20, 2025 by: Seeking Alpha
Sentiment: Positive
I rate Oscar Health as a buy, viewing short-term regulatory headwinds as a buying opportunity given its long-term growth prospects. Oscar's strong revenue growth, improving profitability, and efficient SG&A management support my positive outlook, despite recent bearish analyst coverage. The company's strategic expansion into the ICHRA market and deployment of AI technology are key drivers for future revenue and cost efficiency.
Read More
Is $20 a Fair Valuation for Oscar Health (OSCR) — or a Stretch Too Far?
Published: July 20, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Key Points in This Article: Oscar Health's (OSCR) stock surged in June 2025 due to strong Q1 earnings but crashed after Centene's guidance withdrawal and analyst downgrades.
Read More
Oscar Health, Inc. (OSCR) Surpasses Market Returns: Some Facts Worth Knowing
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Oscar Health, Inc. (OSCR) closed at $15.35 in the latest trading session, marking a +2.88% move from the prior day.
Read More
Why I'm Buying Oscar's Panic Dip
Published: July 03, 2025 by: Seeking Alpha
Sentiment: Negative
Centene's $1.8B ACA risk shock triggered a ~15-20% drop in Oscar's stock but didn't alter Q1 fundamentals. Oscar posted 42% revenue growth, expanding to 2 million members with a record-low 15.8% SG&A expense ratio. Barclays' downgrade highlights policy risk, projecting over 100bps MLR pressure and aggressive EPS cuts if subsidies expire.
Read More
Oscar Health: Should You Buy OSCR Stock At $17?
Published: July 03, 2025 by: Forbes
Sentiment: Neutral
On July 2nd, the health insurance sector underwent a notable decline following Centene (NYSE:CNC)'s retraction of its financial outlook, citing rising costs. Refer to – Centene: Is The Recent Decline In CNC Stock Justified?
Read More
Oscar Health: Should You Buy OSCR Stock At $17?
Published: July 03, 2025 by: Forbes
Sentiment: Neutral
On July 2nd, the health insurance sector underwent a notable decline following Centene (NYSE:CNC)'s retraction of its financial outlook, citing rising costs. Refer to – Centene: Is The Recent Decline In CNC Stock Justified?
Read More
Oscar Health, Inc. (OSCR) Stock Sinks As Market Gains: Here's Why
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Negative
Oscar Health, Inc. (OSCR) concluded the recent trading session at $16.62, signifying a -18.73% move from its prior day's close.
Read More
Oscar Health (OSCR) Soars 7.8%: Is Further Upside Left in the Stock?
Published: June 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Oscar Health (OSCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Read More
Oscar Health: The Healthcare Disruptor Just Hit Its Stride
Published: May 14, 2025 by: Seeking Alpha
Sentiment: Positive
Oscar Health, Inc. delivered strong Q1 results with 42% revenue growth, improved cost control, and expanding membership, signaling sustainable profitability and margin expansion. The company stands to benefit from competitor exits in ACA exchanges and potential policy changes lowering prescription drug costs, enhancing long-term operating leverage. Despite a high current P/E, forward multiples and consensus EPS growth suggest Oscar is undervalued with >41% upside potential in the next 12-18 months.
Read More
Oscar Health, Inc. (OSCR) Q1 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Oscar Health, Inc. (NYSE:OSCR ) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Chris Potochar - Vice President of Treasury and Investor Relations Mark Bertolini - Chief Executive Officer Scott Blackley - Chief Financial Officer Conference Call Participants John Ransom - Raymond James Stephen Baxter - Wells Fargo Jonathan Yong - UBS Joanna Gajuk - Bank of America Josh Raskin - Nephron Research Jessica Tassan - Piper Sandler Michael Ha - Baird David Windley - Jefferies Operator Good morning, everyone. My name is Ellie, and I will be your conference operator for today.
Read More
Oscar Health, Inc. (OSCR) Beats Q1 Earnings and Revenue Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Oscar Health, Inc. (OSCR) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $0.62 per share a year ago.
Read More
Oscar Health Announces Strong Financial Results for First Quarter 2025 And Reaffirms 2025 Guidance
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Oscar Health, Inc. (“Oscar” or the “Company”) (NYSE: OSCR), a leading healthcare technology company, announced today its financial results for the first quarter ended March 31, 2025. “Oscar reported strong financial results in the first quarter,” said Mark Bertolini, CEO of Oscar Health. “We delivered continued top-line growth and bottom-line performance with significant year-over-year increases in revenue and net income. We continue to expect meaningful margin expans.
Read More
Oscar Health, Inc. (OSCR) Increases Despite Market Slip: Here's What You Need to Know
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Negative
In the most recent trading session, Oscar Health, Inc. (OSCR) closed at $13.61, indicating a +1.8% shift from the previous trading day.
Read More
Ataraxis AI to Transform Precision Medicine in Cancer Care with $20.4 Million Series A
Published: March 05, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Ataraxis AI, the leading AI precision medicine company, today announced its $20.4 million Series A financing led by AIX Ventures with participation from Floating Point, Thiel Bio, Founders Fund, Bertelsmann Investments, and existing investors, Giant Ventures and Obvious Ventures. The round also received backing from angel investors and healthcare pioneers, including Mario Schlosser, co-founder and former CEO of Oscar Health (NYSE: OSCR), Ryan Fukushima, COO of Tempus,.
Read More
Shareholders That Lost Money on Oscar Health, Inc. (OSCR) Should Contact Levi & Korsinsky About Securities Fraud Investigation - OSCR
Published: February 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share.
Read More
Shareholder Rights Advocates at Levi & Korsinsky Investigate Oscar Health, Inc. (OSCR) Regarding Possible Securities Fraud Violations
Published: February 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share.
Read More
Michael Burry's latest stock bet is skyrocketing
Published: February 19, 2025 by: Finbold
Sentiment: Positive
Michael Burry of ‘The Big Short' fame earned the admiration of investors all over the world by correctly predicting and profiting off of the 2008 subprime mortgage crisis.
Read More
Oscar Health, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - OSCR
Published: February 13, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Feb. 13, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Oscar Health, Inc. ("Oscar Health" or "the Company") (NYSE: OSCR) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors.
Read More
About Oscar Health, Inc. (OSCR)
- IPO Date 2021-03-03
- Website https://www.hioscar.com
- Industry Medical - Healthcare Plans
- CEO Mark Thomas Bertolini
- Employees 2400